SI3235824T1 - Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata - Google Patents

Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata

Info

Publication number: SI3235824T1
Authority: SI; Slovenia
Prior art keywords: alaninyl; gemcitabine; benzyloxy; phenyl; phosphate
Prior art date: 2012-11-16

Application number

SI201331437T

Other languages

English (en)

Inventor

Christopher Mcguigan

Fabrizio Pertusati

Original Assignee

University College Cardiff Consultants Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-16

Filing date

2013-11-15

Publication date

2019-08-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3235824(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-16 Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en

2013-04-23 Priority claimed from GB201307314A external-priority patent/GB201307314D0/en

2013-11-15 Application filed by University College Cardiff Consultants Limited filed Critical University College Cardiff Consultants Limited

2019-08-30 Publication of SI3235824T1 publication Critical patent/SI3235824T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
- B01J27/06—Halogens; Compounds thereof
- B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
- H01S5/00—Semiconductor lasers
- H01S5/30—Structure or shape of the active region; Materials used for the active region
- H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
- H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
- H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Nanotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Biophysics (AREA)
Crystallography & Structural Chemistry (AREA)
Materials Engineering (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Tropical Medicine & Parasitology (AREA)
AIDS & HIV (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Catalysts (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SI201331437T 2012-11-16 2013-11-15 Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata SI3235824T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1220666.0A GB201220666D0 (en)	2012-11-16	2012-11-16	Process for preparing chemical compounds
GB201307314A GB201307314D0 (en)	2013-04-23	2013-04-23	Process for preparing chemical compounds
EP17169878.0A EP3235824B1 (en)	2012-11-16	2013-11-15	Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate

Publications (1)

Publication Number	Publication Date
SI3235824T1 true SI3235824T1 (sl)	2019-08-30

Family

ID=49622844

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201330652T SI3150616T1 (sl)	2012-11-16	2013-11-15	Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
SI201331437T SI3235824T1 (sl)	2012-11-16	2013-11-15	Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI201330652T SI3150616T1 (sl)	2012-11-16	2013-11-15	Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata

Country Status (28)

Country	Link
US (3)	US10005810B2 (sl)
EP (3)	EP2920192B1 (sl)
JP (5)	JP2016506371A (sl)
KR (1)	KR20150103669A (sl)
CN (2)	CN111592577A (sl)
AU (1)	AU2013346515B2 (sl)
CA (1)	CA2891266C (sl)
CL (1)	CL2015001307A1 (sl)
CY (2)	CY1119161T1 (sl)
DK (2)	DK3235824T3 (sl)
EA (1)	EA028871B1 (sl)
ES (3)	ES2627195T3 (sl)
HR (2)	HRP20170791T1 (sl)
HU (2)	HUE033335T2 (sl)
IL (1)	IL238792A (sl)
IN (1)	IN2015DN04090A (sl)
LT (2)	LT3235824T (sl)
MX (1)	MX374779B (sl)
MY (1)	MY176133A (sl)
NZ (1)	NZ708177A (sl)
PH (1)	PH12015501090B1 (sl)
PL (2)	PL3235824T3 (sl)
PT (2)	PT3235824T (sl)
RS (2)	RS56038B1 (sl)
SG (3)	SG11201503750YA (sl)
SI (2)	SI3150616T1 (sl)
SM (2)	SMT201900341T1 (sl)
WO (1)	WO2014076490A1 (sl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
ES2627195T3 (es) *	2012-11-16	2017-07-27	University College Cardiff Consultants Limited	Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
KR20160099090A (ko) *	2013-11-27	2016-08-19	아이데닉스 파마슈티칼스 엘엘씨	간암의 치료를 위한 뉴클레오티드
CN105153257B (zh) *	2014-06-12	2019-03-05	正大天晴药业集团股份有限公司	索非布韦的制备方法
DK3119794T3 (en)	2014-06-25	2018-01-22	NuCana plc	FORMULA CONTAINING A GEMCITABIN PRODRUG
WO2015198058A1 (en) *	2014-06-25	2015-12-30	Nucana Biomed Limited	Gemcitabine prodrugs
CN105254694B (zh) *	2014-07-14	2018-11-27	正大天晴药业集团股份有限公司	氘代核苷衍生物
CN106795198B (zh)	2014-07-22	2019-09-06	努卡那公共有限公司	用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
CN106661074A (zh) *	2014-07-31	2017-05-10	桑多斯股份公司	磷酰胺的合成
US9675632B2 (en)	2014-08-26	2017-06-13	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
CN105461774B (zh) *	2014-09-30	2020-11-24	江苏豪森药业集团有限公司	索非布韦的制备方法
CN105461773B (zh) *	2014-09-30	2020-12-01	江苏豪森药业集团有限公司	索非布韦的制备方法及其中间体
GB201417644D0 (en) *	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
WO2016073756A1 (en)	2014-11-06	2016-05-12	Enanta Pharmaceuticals, Inc.	Deuterated nucleoside/tide derivatives
US9732110B2 (en)	2014-12-05	2017-08-15	Enanta Pharmaceuticals, Inc.	Nucleoside and nucleotide derivatives
WO2016144918A1 (en)	2015-03-06	2016-09-15	Atea Pharmaceuticals, Inc.	β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2016151542A1 (en)	2015-03-26	2016-09-29	Quimica Sintetica, S.A.	Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) *	2015-07-28	2021-05-11	广东东阳光药业有限公司	一种改良的索菲布韦制备方法
CN106543220A (zh)	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	氨基磷酸酯化合物及其制备方法和晶体
CN106478753A (zh) *	2015-09-16	2017-03-08	博瑞生物医药（苏州）股份有限公司	一种nuc‑1031单一异构体的制备方法和用途
CN106543252A (zh) *	2015-09-16	2017-03-29	博瑞生物医药（苏州）股份有限公司	核苷氨基磷酸酯类前药的制备方法及其中间体
EA037248B1 (ru) *	2015-10-05	2021-02-26	НУКАНА ПиЭлСи	Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
WO2017090264A1 (ja) *	2015-11-27	2017-06-01	大原薬品工業株式会社	５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
WO2017098252A1 (en)	2015-12-11	2017-06-15	Nucana Biomed Limited	Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
GB201522771D0 (en) *	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
GB201609602D0 (en) *	2016-06-01	2016-07-13	Nucuna Biomed Ltd	Chemical compounds
US10202412B2 (en)	2016-07-08	2019-02-12	Atea Pharmaceuticals, Inc.	β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
US10711029B2 (en)	2016-07-14	2020-07-14	Atea Pharmaceuticals, Inc.	Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) *	2016-07-20	2019-03-26	Optimus Drugs (P) Limited	Process for the preparation of sofosbuvir
WO2018019188A1 (zh) *	2016-07-23	2018-02-01	博瑞生物医药（苏州）股份有限公司	核苷氨基磷酸酯类前药的多晶型及其制备方法
SG11201901457TA (en)	2016-09-07	2019-03-28	Atea Pharmaceuticals Inc	2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US10266558B2 (en) *	2016-10-07	2019-04-23	Alexandre Vasilievich Ivachtchenko	Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
CN109863160B (zh) *	2016-12-23	2022-06-07	四川科伦博泰生物医药股份有限公司	核苷磷酸类化合物及其制备方法和用途
IL295609B2 (en)	2017-02-01	2023-11-01	Atea Pharmaceuticals Inc	Nucleotide hemisulfate salt for the treatment of hepatitis C virus
GB201709471D0 (en)	2017-06-14	2017-07-26	Nucana Biomed Ltd	Diastereoselective synthesis of hosphate derivatives
CN112351799A (zh)	2018-04-10	2021-02-09	阿堤亚制药公司	具有硬化的hcv感染患者的治疗
JP2021528363A (ja)	2018-06-12	2021-10-21	シチュアンケルン−バイオテックバイオファーマシューティカルカンパニーリミテッド	ホスホンアミドエステル化合物、その塩、その関連する結晶体、その製造方法及びその使用
US10874687B1 (en)	2020-02-27	2020-12-29	Atea Pharmaceuticals, Inc.	Highly active compounds against COVID-19
RU2740058C1 (ru) *	2020-06-26	2020-12-31	Общество С Ограниченной Ответственностью "Технология Лекарств"	Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) *	2020-12-07	2023-04-21	武汉伯瑞恒医药科技有限公司	阿糖胞苷结构类似物及其制备方法和用途
JP2024525164A (ja)	2021-06-17	2024-07-10	アテアファーマシューティカルズ，インコーポレイテッド	有利な抗ｈｃｖ併用療法
CN113549076B (zh) *	2021-07-23	2022-12-06	中国药科大学	一种多取代嘌呤类化合物及其制备方法和应用
WO2024107859A1 (en) *	2022-11-15	2024-05-23	Rome Therapeutics, Inc.	Cyclopentene-oxymethylene phosphonamidates and related compounds and their use in treating medical conditions

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5827727A (en)	1990-02-01	1998-10-27	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5204466A (en) *	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US7462605B2 (en)	1998-01-23	2008-12-09	Celmed Oncology (Usa), Inc.	Phosphoramidate compounds and methods of use
ES2172303T3 (es)	1998-01-23	2002-09-16	Newbiotics Inc	Agentes terapeuticos obtenidos por catalisis enzimatica.
WO2003068162A2 (en)	2002-02-14	2003-08-21	Pharmasset Ltd.	Modified fluorinated nucleoside analogues
AU2003291726A1 (en)	2002-11-04	2004-06-07	Xenoport, Inc.	Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) *	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
GB0505781D0 (en) *	2005-03-21	2005-04-27	Univ Cardiff	Chemical compounds
CN101287472B (zh) *	2005-08-15	2011-10-12	弗·哈夫曼-拉罗切有限公司	抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物
GB0623493D0 (en) *	2006-11-24	2007-01-03	Univ Cardiff	Chemical compounds
US7964580B2 (en) *	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) *	2008-12-08	2010-07-27	Medivir Ab	Nucleótidos uracil ciclopropílicos
CA2749394A1 (en)	2009-01-09	2010-07-15	University College Of Cardiff Consultants Limited	Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
JP5872539B2 (ja) *	2010-03-31	2016-03-01	ギリアドファーマセットエルエルシー	プリンヌクレオシドホスホルアミダート
EP2805960A1 (en)	2010-07-19	2014-11-26	Gilead Sciences, Inc.	Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
US8871737B2 (en) *	2010-09-22	2014-10-28	Alios Biopharma, Inc.	Substituted nucleotide analogs
EP2655392B1 (en) *	2010-12-22	2018-04-18	Alios Biopharma, Inc.	Cyclic nucleotide analogs
HRP20160346T1 (hr) *	2011-03-01	2016-05-06	Nucana Biomed Limited	Fosforoamidatni derivati 5-fluoro-2'-deoksiuridina za upotrebu u tretmanu raka
KR20190060879A (ko) *	2011-03-02	2019-06-03	제롬 쉔타그	단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
AU2012323937A1 (en) *	2011-10-14	2014-06-05	Stc.Unm	Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
ES2627195T3 (es) *	2012-11-16	2017-07-27	University College Cardiff Consultants Limited	Mezcla de RP/SP gemcitabina-[fenil-(bencloxi-l-alaninil)]-fosfato
CA2913206C (en) *	2013-06-26	2022-08-02	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
ES2927955T3 (es)	2013-09-11	2022-11-14	Univ Emory	Composiciones de nucleótidos y nucleósidos y sus usos
WO2015054465A1 (en) *	2013-10-11	2015-04-16	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
CA2931804A1 (en) *	2013-11-27	2015-06-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Piperidine and piperazine derivatives and their use in treating viral infections and cancer
KR20160099090A (ko)	2013-11-27	2016-08-19	아이데닉스 파마슈티칼스 엘엘씨	간암의 치료를 위한 뉴클레오티드
WO2015198058A1 (en)	2014-06-25	2015-12-30	Nucana Biomed Limited	Gemcitabine prodrugs
DK3119794T3 (en)	2014-06-25	2018-01-22	NuCana plc	FORMULA CONTAINING A GEMCITABIN PRODRUG
CN106795198B (zh)	2014-07-22	2019-09-06	努卡那公共有限公司	用于制备吉西他滨-[苯基(苄氧基-l-丙氨酸基)]磷酸酯的方法
GB201417644D0 (en)	2014-10-06	2014-11-19	Nucana Biomed Ltd	Method of separating phosphate diastereoisomers
MX390506B (es)	2015-05-14	2025-03-20	NuCana plc	Nuc-1031 (gemcitabina-[fenil-benzoxi-l-alaninil])-fosfato) para usarse en el tratamiento neoadyuvante y adyuvante en pacientes con cáncer.
EA037248B1 (ru)	2015-10-05	2021-02-26	НУКАНА ПиЭлСи	Применение гемцитабин[фенил-бензокси-l-аланинил]фосфата в комбинации с карбоплатином
WO2017098252A1 (en)	2015-12-11	2017-06-15	Nucana Biomed Limited	Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031
AU2015418015B2 (en)	2015-12-23	2021-12-09	NuCana plc	Combination therapy
ES2778933T3 (es)	2015-12-23	2020-08-12	NuCana plc	Terapia de combinación
GB201522771D0 (en)	2015-12-23	2016-02-03	Nucana Biomed Ltd	Crystalline form of a phosphate derivative
GB201713914D0 (en)	2017-08-30	2017-10-11	Nucana Biomed Ltd	Combination therapy
JP2020171815A (ja) *	2020-07-29	2020-10-22	株式会社ユニバーサルエンターテインメント	プログラム

2013
- 2013-11-15 ES ES16195036.5T patent/ES2627195T3/es active Active
- 2013-11-15 SM SM20190341T patent/SMT201900341T1/it unknown
- 2013-11-15 MY MYPI2015001314A patent/MY176133A/en unknown
- 2013-11-15 SG SG11201503750YA patent/SG11201503750YA/en unknown
- 2013-11-15 SG SG10201510324YA patent/SG10201510324YA/en unknown
- 2013-11-15 NZ NZ708177A patent/NZ708177A/en not_active IP Right Cessation
- 2013-11-15 PT PT17169878T patent/PT3235824T/pt unknown
- 2013-11-15 LT LTEP17169878.0T patent/LT3235824T/lt unknown
- 2013-11-15 IN IN4090DEN2015 patent/IN2015DN04090A/en unknown
- 2013-11-15 WO PCT/GB2013/053018 patent/WO2014076490A1/en not_active Ceased
- 2013-11-15 PL PL17169878T patent/PL3235824T3/pl unknown
- 2013-11-15 AU AU2013346515A patent/AU2013346515B2/en not_active Ceased
- 2013-11-15 EP EP13792965.9A patent/EP2920192B1/en not_active Not-in-force
- 2013-11-15 HU HUE16195036A patent/HUE033335T2/en unknown
- 2013-11-15 KR KR1020157015861A patent/KR20150103669A/ko not_active Ceased
- 2013-11-15 ES ES17169878T patent/ES2725491T3/es active Active
- 2013-11-15 PT PT161950365T patent/PT3150616T/pt unknown
- 2013-11-15 DK DK17169878.0T patent/DK3235824T3/da active
- 2013-11-15 CN CN202010526209.7A patent/CN111592577A/zh active Pending
- 2013-11-15 DK DK16195036.5T patent/DK3150616T3/en active
- 2013-11-15 EP EP16195036.5A patent/EP3150616B1/en active Active
- 2013-11-15 CN CN201380069952.2A patent/CN104903339A/zh active Pending
- 2013-11-15 LT LTEP16195036.5T patent/LT3150616T/lt unknown
- 2013-11-15 RS RS20170506A patent/RS56038B1/sr unknown
- 2013-11-15 HU HUE17169878 patent/HUE044605T2/hu unknown
- 2013-11-15 JP JP2015542357A patent/JP2016506371A/ja active Pending
- 2013-11-15 EA EA201590955A patent/EA028871B1/ru unknown
- 2013-11-15 PL PL16195036T patent/PL3150616T3/pl unknown
- 2013-11-15 SI SI201330652T patent/SI3150616T1/sl unknown
- 2013-11-15 EP EP17169878.0A patent/EP3235824B1/en active Active
- 2013-11-15 SI SI201331437T patent/SI3235824T1/sl unknown
- 2013-11-15 SG SG10201510322UA patent/SG10201510322UA/en unknown
- 2013-11-15 ES ES13792965.9T patent/ES2618732T3/es active Active
- 2013-11-15 CA CA2891266A patent/CA2891266C/en active Active
- 2013-11-15 US US14/442,987 patent/US10005810B2/en active Active
- 2013-11-15 MX MX2015006195A patent/MX374779B/es active IP Right Grant
- 2013-11-15 SM SM20170349T patent/SMT201700349T1/it unknown
- 2013-11-15 RS RS20190549A patent/RS58849B1/sr unknown
2015
- 2015-05-13 IL IL238792A patent/IL238792A/en active IP Right Grant
- 2015-05-14 CL CL2015001307A patent/CL2015001307A1/es unknown
- 2015-05-15 PH PH12015501090A patent/PH12015501090B1/en unknown
2017
- 2017-05-24 CY CY20171100539T patent/CY1119161T1/el unknown
- 2017-05-29 HR HRP20170791TT patent/HRP20170791T1/hr unknown
- 2017-08-10 JP JP2017154931A patent/JP2018009000A/ja not_active Withdrawn
2018
- 2018-05-31 US US15/994,378 patent/US11040997B2/en active Active
2019
- 2019-05-06 HR HRP20190831TT patent/HRP20190831T1/hr unknown
- 2019-05-09 CY CY20191100503T patent/CY1121663T1/el unknown
- 2019-06-18 JP JP2019112739A patent/JP2019196360A/ja active Pending
2020
- 2020-10-12 JP JP2020171815A patent/JP7519259B2/ja active Active
2021
- 2021-05-18 US US17/323,367 patent/US20220033433A1/en not_active Abandoned
2023
- 2023-01-20 JP JP2023007007A patent/JP2023052536A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
HK1210784A1 (en)	2016-05-06
US20150291650A1 (en)	2015-10-15
SI3150616T1 (sl)	2017-08-31
JP2023052536A (ja)	2023-04-11
EP2920192B1 (en)	2017-02-22
RS56038B1 (sr)	2017-09-29
US11040997B2 (en)	2021-06-22
IL238792A0 (en)	2015-06-30
JP2019196360A (ja)	2019-11-14
ES2725491T3 (es)	2019-09-24
EP3235824A1 (en)	2017-10-25
CN111592577A (zh)	2020-08-28
DK3235824T3 (da)	2019-05-20
ES2627195T3 (es)	2017-07-27
ES2618732T3 (es)	2017-06-22
HUE044605T2 (hu)	2019-11-28
EP3235824B1 (en)	2019-03-27
AU2013346515A1 (en)	2015-06-04
WO2014076490A1 (en)	2014-05-22
PT3235824T (pt)	2019-05-30
HUE033335T2 (en)	2017-11-28
EP3150616B1 (en)	2017-05-10
JP2016506371A (ja)	2016-03-03
LT3235824T (lt)	2019-07-10
KR20150103669A (ko)	2015-09-11
US20180273575A1 (en)	2018-09-27
AU2013346515B2 (en)	2017-05-25
SG10201510324YA (en)	2016-01-28
CA2891266C (en)	2020-12-08
EA028871B1 (ru)	2018-01-31
IL238792A (en)	2017-09-28
EP3150616A1 (en)	2017-04-05
MY176133A (en)	2020-07-24
LT3150616T (lt)	2017-07-25
MX374779B (es)	2025-03-06
CA2891266A1 (en)	2014-05-22
PT3150616T (pt)	2017-06-09
JP2021020919A (ja)	2021-02-18
IN2015DN04090A (sl)	2015-10-09
PH12015501090A1 (en)	2015-07-27
SMT201700349T1 (it)	2017-09-07
SG11201503750YA (en)	2015-06-29
PL3235824T3 (pl)	2019-09-30
NZ708177A (en)	2017-08-25
RS58849B1 (sr)	2019-07-31
SG10201510322UA (en)	2016-01-28
CY1119161T1 (el)	2018-02-14
US20220033433A1 (en)	2022-02-03
US10005810B2 (en)	2018-06-26
BR112015011155A2 (pt)	2017-07-11
MX2015006195A (es)	2015-12-08
PL3150616T3 (pl)	2017-09-29
CY1121663T1 (el)	2020-07-31
EA201590955A1 (ru)	2015-08-31
SMT201900341T1 (it)	2019-07-11
JP7519259B2 (ja)	2024-07-19
CL2015001307A1 (es)	2015-12-11
EP2920192A1 (en)	2015-09-23
CN104903339A (zh)	2015-09-09
PH12015501090B1 (en)	2019-01-30
JP2018009000A (ja)	2018-01-18
DK3150616T3 (en)	2017-06-06
HRP20190831T1 (hr)	2019-08-23
HRP20170791T1 (hr)	2017-08-25

Publication	Publication Date	Title
SI3235824T1 (sl)	2019-08-30	Zmes rp / sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
IL235185A0 (en)	2014-12-31	mirna modulators of thermogenesis
SG11201504049VA (en)	2015-07-30	Compounds and their methods of use
ZA201405746B (en)	2015-11-25	Rafamycin analogs and methods for making same
ZA201406082B (en)	2019-01-30	Use of ccr3-inhibitors
ZA201405535B (en)	2017-08-30	Inhibitors of iap
ZA201209245B (en)	2013-08-28	Rubber mixture
IL219244A0 (en)	2012-07-31	Splitting of user-lists
GB201501016D0 (en)	2015-03-04	Preparation of 18F-fluciclovine
PL2922628T3 (pl)	2018-02-28	Mieszanka odtłuszczająca
PL2888228T3 (pl)	2019-10-31	Inhibitory oddziaływania CD40-TRAF6
GB201207907D0 (en)	2012-06-20	Treatment of depression
GB2500066B (en)	2018-04-11	Fire start facilitator
GB201209895D0 (en)	2012-07-18	Use of a composition
GB201217666D0 (en)	2012-11-14	Construction of surfaces